BACKGROUND AND OBJECTIVES: Many patients with post-traumatic stress disorder (PTSD) achieve but partial remission with current treatments. Patients with unremitted PTSD show high rates of substance abuse. Marijuana is often used as compassion add-on therapy for treatment-resistant PTSD. This open-label study evaluates the tolerance and safety of orally absorbable Δ(9)-tetrahydrocannabinol (THC) for chronic PTSD. METHODS: Ten outpatients with chronic PTSD, on stable medication, received 5 mg of Δ(9)-THC twice a day as add-on treatment. RESULTS: There were mild adverse effects in three patients, none of which led to treatment discontinuation. The intervention caused a statistically significant improvement in global symptom severity, sleep quality, frequency of nightmares, and PTSD hyperarousal symptoms. CONCLUSIONS: Orally absorbable Δ(9)-THC was safe and well tolerated by patients with chronic PTSD.
BACKGROUND AND OBJECTIVES: Many patients with post-traumatic stress disorder (PTSD) achieve but partial remission with current treatments. Patients with unremitted PTSD show high rates of substance abuse. Marijuana is often used as compassion add-on therapy for treatment-resistant PTSD. This open-label study evaluates the tolerance and safety of orally absorbable Δ(9)-tetrahydrocannabinol (THC) for chronic PTSD. METHODS: Ten outpatients with chronic PTSD, on stable medication, received 5 mg of Δ(9)-THC twice a day as add-on treatment. RESULTS: There were mild adverse effects in three patients, none of which led to treatment discontinuation. The intervention caused a statistically significant improvement in global symptom severity, sleep quality, frequency of nightmares, and PTSD hyperarousal symptoms. CONCLUSIONS: Orally absorbable Δ(9)-THC was safe and well tolerated by patients with chronic PTSD.
Authors: Margaret Haney; Erik W Gunderson; Judith Rabkin; Carl L Hart; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin Journal: J Acquir Immune Defic Syndr Date: 2007-08-15 Impact factor: 3.731
Authors: A Neumeister; M D Normandin; R H Pietrzak; D Piomelli; M Q Zheng; A Gujarro-Anton; M N Potenza; C R Bailey; S F Lin; S Najafzadeh; J Ropchan; S Henry; S Corsi-Travali; R E Carson; Y Huang Journal: Mol Psychiatry Date: 2013-05-14 Impact factor: 15.992
Authors: Alexander Neumeister; Jordan Seidel; Benjamin J Ragen; Robert H Pietrzak Journal: Psychoneuroendocrinology Date: 2014-10-22 Impact factor: 4.905
Authors: Ruth A Lanius; Jenna E Boyd; Margaret C McKinnon; Andrew A Nicholson; Paul Frewen; Eric Vermetten; Rakesh Jetly; David Spiegel Journal: Curr Psychiatry Rep Date: 2018-11-07 Impact factor: 5.285